Research Papers:
Matrine derivative YF18 inhibits lung cancer cell proliferation and migration through downregulating Skp2
PDF | Full Text | How to cite
Lichuan Wu1,*, Guizhen Wang2,*, Jinrui Wei3,*, Na Huang4,*, Sen Zhang1, Fangfang Yang1, Ming Li5, Guangbiao Zhou2, Lisheng Wang1
1School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi, PR China
2State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, PR China
3Guangxi Scientific Research Center of Traditional Chinese Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, PR China
4Affiliated Tumour Hospital of Guangxi Medical University, Nanning, Guangxi, PR China
5Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, PR China
*These authors contributed equally to this work
Correspondence to:
Lichuan Wu, email: wulichuan@126.com
Lisheng Wang, email: w_lsheng@163.com
Keywords: lung cancer, matrine derivative, Skp2, proliferation, migration
Received: May 17, 2016 Accepted: December 16, 2016 Published: December 28, 2016
ABSTRACT
Lung cancer is the leading cause of cancer related death which needs novel drugs to improve patient outcomes. In this study, we examined the ability of YF-18, a novel matrine derivative to inhibit the growth and migration of lung cancer cells. By cell cycle analysis, wound healing and transwell assays, we found that YF-18 induced G2/M cell cycle arrest and inhibited migration of lung cancer cells in a dose-dependent manner. Further results indicated that YF-18 inhibited cell proliferation and migration through down-regulating Skp2 and up-regulating its substrates, p27 and E-cadherin. Moreover, YF-18 inhibited A549-luciferase cell xenograft tumor growth in a dose-dependent manner. The findings indicate that YF-18 bears therapeutic potentials for lung cancer.